Marel SVD, Majowicz A, Deventer SV, Petry H, Hommes DW, Ferreira V. Gene and cell therapy based treatment strategies for inflammatory bowel diseases. World J Gastrointest Pathophysiol 2011; 2(6): 114-122 [PMID: 22180846 DOI: 10.4291/wjgp.v2.i6.114]
Corresponding Author of This Article
Sander van der Marel, MD, Department of Research and Development, Amsterdam Molecular Therapeutics BV, Meibergdreef 61, 1105 BA Amsterdam, The Netherlands. s.vandermarel@amtbiopharma.com
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pathophysiol. Dec 15, 2011; 2(6): 114-122 Published online Dec 15, 2011. doi: 10.4291/wjgp.v2.i6.114
Gene and cell therapy based treatment strategies for inflammatory bowel diseases
Sander van der Marel, Anna Majowicz, Sander van Deventer, Harald Petry, Daniel W Hommes, Valerie Ferreira
Sander van der Marel, Anna Majowicz, Sander van Deventer, Harald Petry, Valerie Ferreira, Department of Research and Development, Amsterdam Molecular Therapeutics BV, 1105 BA Amsterdam, The Netherlands
Sander van der Marel, Anna Majowicz, Sander van Deventer, Daniel W Hommes, Department of Gastroenterology and Hepatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
Author contributions: van der Marel S and Ferreira V performed literature searches, wrote the review and made editorial corrections; Majowicz A, van Deventer S, Petry H and Hommes DW contributed conceptually to the work, reviewed the manuscript and assisted with the editing of the paper.
Supported by A grant from the Broad Medical Research Program of The Broad Foundation, Proposal No. IBD-029 5R (to van der Marel S and Hommes DW)
Correspondence to: Sander van der Marel, MD, Department of Research and Development, Amsterdam Molecular Therapeutics BV, Meibergdreef 61, 1105 BA Amsterdam, The Netherlands. s.vandermarel@amtbiopharma.com
Telephone: +31-20-56634 39 Fax: +31-20-5669272
Received: May 28, 2011 Revised: August 12, 2011 Accepted: August 19, 2011 Published online: December 15, 2011
Abstract
Inflammatory bowel diseases (IBD) are a group of chronic inflammatory disorders most commonly affecting young adults. Currently available therapies can result in induction and maintenance of remission, but are not curative and have sometimes important side effects. Advances in basic research in IBD have provided new therapeutic opportunities to target the inflammatory process involved. Gene and cell therapy approaches are suitable to prevent inflammation in the gastrointestinal tract and show therefore potential in the treatment of IBD. In this review, we present the current progress in the field of both gene and cell therapy and future prospects in the context of IBD. Regarding gene therapy, we focus on viral vectors and their applications in preclinical models. The focus for cell therapy is on regulatory T lymphocytes and mesenchymal stromal cells, their potential for the treatment of IBD and the progress made in both preclinical models and clinical trials.
